Cambridge/Boston, MA, USA – 18th January 2024. Vivtex Corporation (“Vivtex”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, and AI Proteins, Inc., a growing biotechnology company that utilizes computational de novo protein design to create novel therapeutic miniproteins, today announced they have entered a strategic R&D collaboration to develop novel, oral biologic therapies for inflammatory diseases.

剑桥/波士顿，马萨诸塞州，美国–2024年1月18日。Vivtex Corporation（“Vivtex”）是一家旨在改变主要疾病口服生物疗法发展的生物技术公司，AI Proteins，Inc.是一家不断发展的生物技术公司，利用计算从头蛋白质设计来创造新型治疗性小蛋白，今天宣布，他们已经进入战略研发合作，以开发新型，炎症性疾病的口服生物疗法。

The partners will leverage Vivtex’s proprietary and extensively validated GI-ORIS™ (“Gut on a chip” and AI) screening and formulation platform technology to evaluate and enhance the oral bioavailability of AI Proteins’ miniproteins designed to target and inhibit the activity of the TNF receptor 1 (TNFR1).

合作伙伴将利用Vivtex专有且经过广泛验证的GI-ORIS™ （“芯片上的肠道”和AI）筛选和配方平台技术，用于评估和提高AI蛋白微蛋白的口服生物利用度，该微蛋白旨在靶向和抑制TNF受体1（TNFR1）的活性。

Under the agreement, the companies will jointly conduct and share the costs of the program and will co-own any resulting data. No further financial details are disclosed. Preventing inflammation by inhibiting TNF-alpha (tumor necrosis factor alpha) signaling is a highly validated approach and the mechanism of action of multiple approved biologic products that generate multi-billion-dollar revenues each year.

根据该协议，两家公司将共同执行并分担该计划的费用，并将共同拥有由此产生的任何数据。没有披露进一步的财务细节。通过抑制TNF-α（肿瘤坏死因子-α）信号传导来预防炎症是一种高度验证的方法，也是多种批准的生物产品的作用机制，每年产生数十亿美元的收入。

There are multiple receptors for TNF-alpha and inhibition of TNFR1, which is responsible for mediating pro-inflammatory signaling activity, has the potential to be a safe and highly effective target for inhibiting this clinically important pathway. There are no FDA approved therapeutics that inhibit TNFR1, with several companies having tried and failed.

TNF-α有多种受体，TNFR1的抑制作用负责介导促炎信号传导活性，有可能成为抑制这一临床重要途径的安全高效靶点。没有FDA批准的抑制TNFR1的疗法，几家公司已经尝试过但失败了。

AI Proteins’ de novo design process provides complete control over miniprotein properties and activity allowing them to achieve remarkable potency and novel receptor engagement to successfully drug TNFR1. With current TNF-alpha pathway inhibitors being injectables,.

AI蛋白的从头设计过程提供了对微蛋白特性和活性的完全控制，使其能够实现显着的效力和新的受体参与，从而成功地制备TNFR1。目前的TNF-α途径抑制剂是可注射的，。